HPSE and neoplasm: Although various strategies such as local delivery of CAR T cells, targeting tumor-related cellular and physical barriers (e.g. generation of anti-FAP CAR T cells targeting CAFs and CAR T cells to overexpress heparanase, an ECM-degrading enzyme) and targeting abnormal tumor vascularity (e.g. generation of CAR T cells targeting VEGFR2 expressed tumor‐associated blood vessels) have been employed to overcome CAR T cell infiltration, genetic modification of chemokine receptors, among the others, has been the most common strategy to improve CAR T cell infiltration into the tumor bed (82–84).